Mylan Hungary Kft,

Mylan Hungary Kft. is a pharmaceutical importer and buyer based in Komárom, Hungary. Established on June 14, 2010, the company operates as a subsidiary of Viatris, a global healthcare entity formed in 2020 through the merger of Mylan N.V. and Upjohn, Pfizer's off-patent medicine division. Mylan Hungary Kft. specializes in the marketing, sales, and distribution of generic and specialty medicines across various therapeutic areas within Hungary. The company's strategic focus emphasizes enhancing access to medicines, expanding its portfolio, and ensuring a reliable pharmaceutical supply chain.

Mylan Hungary Kft. operates a centralized distribution model from its headquarters in Komárom, Hungary. While specific warehouse locations and logistics capabilities are not publicly detailed, the company's extensive import activities suggest a well-established infrastructure capable of managing a diverse product portfolio. The distribution network primarily serves the Hungarian market, ensuring the availability of a wide range of pharmaceutical products to meet local healthcare needs.

As a pharmaceutical importer and buyer, Mylan Hungary Kft. plays a pivotal role in Hungary's pharmaceutical supply chain. The company sources a variety of finished pharmaceutical formulations from international suppliers, including a significant volume from India. By importing and distributing these products, Mylan Hungary Kft. ensures the availability of essential medications across Hungary, thereby contributing to the country's healthcare infrastructure.

Mylan Hungary Kft. demonstrates a high degree of sourcing concentration, with a substantial portion of its imports originating from a single supplier, Mylan Laboratories Limited. This single-source dependency may pose risks related to supply chain disruptions, pricing fluctuations, and potential regulatory changes affecting the supplier. The company's reliance on a single supplier indicates a strategic choice to maintain consistency and quality in its product offerings. However, the limited supplier base may also impact the company's ability to negotiate favorable terms and diversify its product range.

The resilience of Mylan Hungary Kft.'s Indian supply chain is influenced by its reliance on a single supplier, Mylan Laboratories Limited. This dependency may expose the company to risks such as supply disruptions, regulatory changes, and geopolitical factors affecting trade relations. The lack of backup suppliers and limited formulation diversity further heightens these risks. To enhance supply chain resilience, Mylan Hungary Kft. could consider diversifying its supplier base and incorporating a broader range of formulations to mitigate potential disruptions.

Mylan Hungary Kft.'s sourcing pattern, characterized by a high concentration on a single supplier, positions the company to benefit from streamlined operations and potentially favorable terms. However, this strategy also exposes the company to risks associated with supply chain disruptions and limited negotiation leverage. For Indian exporters, this presents an opportunity to establish relationships with Mylan Hungary Kft. by offering alternative products or formulations that align with the company's therapeutic focus, thereby reducing its dependency on a single supplier.

In Hungary, the National Institute of Pharmacy and Nutrition (OGYÉI) serves as the primary regulatory authority overseeing pharmaceutical imports. Key legislation governing pharmaceutical imports includes the Act XCV of 2005 on Medicinal Products and the Government Decree 44/2005 (IV. 5.) on the Detailed Rules of Medicinal Products. The marketing authorization pathway for Indian generics involves obtaining approval from OGYÉI, which includes submitting a dossier demonstrating the product's quality, safety, and efficacy, as well as compliance with Good Manufacturing Practice (GMP) standards.

Import licensing requirements for pharmaceutical products in Hungary necessitate that importers hold a valid wholesale distribution authorization issued by OGYÉI. Additionally, imported products must be accompanied by a GMP certificate recognized by the European Union, WHO, or PIC/S. This ensures that the manufacturing processes meet international quality standards, thereby safeguarding public health.

Imported pharmaceutical products are subject to batch testing and stability requirements to ensure their safety and efficacy. Labeling must be in Hungarian and include essential information such as the product's name, active ingredients, dosage form, strength, and instructions for use. Serialization mandates are in place to facilitate traceability and prevent counterfeit products from entering the market.

Between 2024 and 2026, Hungary implemented policy changes affecting pharmaceutical imports, including stricter enforcement of GMP compliance and enhanced scrutiny of import licenses. These measures aim to improve the quality and safety of imported medicines. Indian pharmaceutical exporters must stay informed about these regulatory updates to ensure continued market access.

Mylan Hungary Kft.'s product category focus on cardiovascular, analgesics & antipyretics, and gastrointestinal medications aligns with prevalent health concerns in Hungary. The significant import volumes in these therapeutic areas indicate strong market demand and the company's strategic emphasis on addressing critical health issues. This focus enables Mylan Hungary Kft. to cater effectively to the therapeutic needs of the Hungarian population.

Mylan Hungary Kft. primarily sources generic pharmaceutical products, with a notable emphasis on formulations such as Simvastatin, Enalapril, Gliclazide, Pravastatin, Atovaquone, and Proguanil. India plays a crucial role in the company's procurement strategy, serving as a key supplier for these formulations. The company's sourcing strategy reflects a commitment to providing cost-effective and essential medications to the Hungarian market.

Based on its product mix, Mylan Hungary Kft. serves multiple segments of the Hungarian pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's diverse product portfolio enables it to meet the needs of various healthcare providers and patients, thereby strengthening its position in the market.

There is a realistic opportunity for new Indian suppliers to collaborate with Mylan Hungary Kft. by offering alternative products or formulations that align with the company's therapeutic focus. Identifying gaps in Mylan Hungary Kft.'s current sourcing, such as underrepresented therapeutic areas or formulations, can provide avenues for new suppliers to enter the market. Establishing relationships with Mylan Hungary Kft. can lead to mutually beneficial partnerships and expanded market reach.

Indian exporters seeking to supply Mylan Hungary Kft. and the Hungarian market must obtain a wholesale distribution authorization from OGYÉI. Additionally, products must be accompanied by a GMP certificate recognized by the European Union, WHO, or PIC/S. Compliance with Hungarian labeling requirements, including the use of the Hungarian language and adherence to serialization mandates, is also essential.

To build a relationship with Mylan Hungary Kft., Indian exporters should initiate contact through formal channels, presenting their product portfolios and demonstrating compliance with Hungarian regulatory standards. Participating in tenders and engaging in regulatory filing strategies that align with Hungarian requirements can enhance the likelihood of successful collaboration. Understanding the regulatory framework and maintaining open communication with Mylan Hungary Kft. are crucial steps in establishing a fruitful partnership.